肺癌PD1／PD-L1免疫检查点治疗疗效预测标志物第18届世界肺癌大会相关研究综述

Predictive Markers for Treating Efficacy of PD-1/PD-L1 Inhibitors in Patients with Lung Cancer: A Review of the 18^(th) World Conference on Lung Cancer

程序化死亡受体-1(programmed cell death-1, PD-1)/程序化死亡受体的配体(programmed cell deathligand 1, PD-L1)免疫检查点抑制剂治疗非小细胞肺癌(non-small cell lung cancer, NSCLC)是近年来最引人注目的进展之一,但目前尚无明确的疗效预测标志物,研究者期望找到明确的标志物来筛选免疫治疗有效的患者,最大程度地让患者获益。第18届世界肺癌大会有关PD-1/PD-L1免疫治疗疗效预测的标志物的研究成为热点。本综述整理分析本次大会上关于肺癌免疫治疗标志物的内容,归纳为以下6个方面:PD-L1表达、肿瘤突变负荷及基因突变修复能力、肿瘤驱动基因突变、免疫效应标志物、血细胞计数、综合分析模型,以帮助临床医生选择合适的生物标志物来筛选能够获益的患者和对治疗疗效进行有效评估。

Programmed cell death-1 （PD-1）/programmed cell death-ligand 1 （PD-L1） checkpoint blockades have dramatically changed the treatment of non-small cell lung cancer （NSCLC）. But we still have no definite biomarkers that may predict the efficacy of treatment by PD- 1/PD-L 1 inhibitors. In the 18th World Conference on Lung Cancer, the biomarkers that may predict the efficacy of treatment by PD-1/PD-L1 inhibitors in patients with lung cancer has been a popular topic, and it has huge potential in the future. In order to enable more patients to get more benefits from treatment, researchers are looking forward to finding the optimum biomarkers. By organizing and summarizing the information about the biomarkers predicting PD-1/PD-L1 in patients with lung cancer, this review mainly focused on the following six aspects to introduce： expression of PD-L 1; tumor mutational burden and the ability of mutation repair, malignant tumor driver mutation, biomarker of immuno- logical effect, blood cell account, comprehensive analysis model. We are hoping to help doctors to find the best biomarker, then much more lung cancer patients could obtain antitumor effects in PD- 1/PD-L 1 inhibitors treatment.